High-dose	O	O
growth	O	O
hormone	O	O
does	O	O
not	O	O
affect	O	O
proinflammatory	O	O
cytokine	O	O
(	O	O
tumor	O	O
necrosis	O	O
factor-alpha	O	O
,	O	O
interleukin-6	O	O
,	O	O
and	O	O
interferon-gamma	O	O
)	O	O
release	O	O
from	O	O
activated	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
or	O	O
after	O	O
minimal	O	O
to	O	O
moderate	O	O
surgical	O	O
stress	O	O
.	O	O

High-dose	O	O
GH	O	O
therapy	O	O
,	O	O
with	O	O
GH	O	O
doses	O	O
10-20	O	O
times	O	O
the	O	O
normal	O	O
replacement	O	O
dose	O	O
for	O	O
GH-deficient	O	O
adults	O	O
,	O	O
has	O	O
been	O	O
used	O	O
as	O	O
an	O	O
anti-catabolic	O	O
agent	O	O
in	O	O
a	O	O
number	O	O
of	O	O
different	O	O
patient	O	O
groups	O	O
.	O	O

A	O	O
recent	O	O
study	O	O
,	O	O
however	O	O
,	O	O
has	O	O
shown	O	O
an	O	O
increase	O	O
in	O	O
mortality	O	O
in	O	O
critically	O	O
ill	O	O
patients	O	O
treated	O	O
with	O	O
high-dose	O	O
GH	O	O
.	O	O

The	O	O
increased	O	O
mortality	O	O
was	O	O
associated	O	O
with	O	O
multiorgan	O	O
failure	O	O
,	O	O
septic	O	O
shock	O	O
,	O	O
and	O	O
uncontrolled	O	O
infection	O	O
,	O	O
suggesting	O	O
that	O	O
GH	O	O
may	O	O
have	O	O
altered	O	O
the	O	O
immune	O	O
response	O	O
.	O	O

The	O	O
GH	B-protein	O
receptor	I-protein	O
and	O	O
GH	O	O
are	O	O
both	O	O
expressed	O	O
in	O	O
peripheral	B-cell_type	O
blood	I-cell_type	O
mononuclear	I-cell_type	O
cells	I-cell_type	O
(	O	O
PBMCs	O	O
)	O	O
;	O	O
thus	O	O
,	O	O
GH	O	O
could	O	O
act	O	O
as	O	O
either	O	O
an	O	O
endocrine	O	O
or	O	O
an	O	O
autocrine	O	O
modulator	O	O
of	O	O
the	O	O
immune	O	O
response	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
hypothesis	O	O
that	O	O
high-dose	O	O
GH	O	O
therapy	O	O
may	O	O
induce	O	O
proinflammatory	O	O
cytokines	O	O
,	O	O
which	O	O
are	O	O
implicated	O	O
in	O	O
septic	O	O
shock	O	O
.	O	O

To	O	O
do	O	O
this	O	O
we	O	O
measured	O	O
cytokine	B-protein	O
production	O	O
by	O	O
PBMCs	O	O
incubated	O	O
in	O	O
conditions	O	O
that	O	O
simulated	O	O
high-dose	O	O
GH	O	O
therapy	O	O
,	O	O
and	O	O
we	O	O
measured	O	O
cytokine	O	O
levels	O	O
in	O	O
patients	O	O
undergoing	O	O
laparoscopic	O	O
cholecystectomy	O	O
who	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
high-dose	O	O
GH	O	O
therapy	O	O
(	O	O
13	O	O
IU/m2	O	O
x	O	O
day	O	O
)	O	O
or	O	O
placebo	O	O
.	O	O

To	O	O
confirm	O	O
the	O	O
biological	O	O
activity	O	O
of	O	O
GH	O	O
in	O	O
our	O	O
cell	O	O
culture	O	O
system	O	O
we	O	O
used	O	O
a	O	O
Stat5	O	O
functional	O	O
assay	O	O
.	O	O

In	O	O
this	O	O
assay	O	O
GH	O	O
induced	O	O
a	O	O
bell-shaped	O	O
curve	O	O
,	O	O
with	O	O
a	O	O
maximal	O	O
response	O	O
at	O	O
GH	O	O
levels	O	O
between	O	O
100-1	O	O
,	O	O
000	O	O
ng/mL	O	O
.	O	O

PBMCs	O	O
from	O	O
healthy	O	O
volunteers	O	O
were	O	O
incubated	O	O
with	O	O
GH	O	O
in	O	O
doses	O	O
from	O	O
1-1	O	O
,	O	O
000	O	O
ng/mL	O	O
for	O	O
6-72	O	O
h	O	O
under	O	O
resting	O	O
conditions	O	O
and	O	O
after	O	O
activation	O	O
with	O	O
endotoxin	O	O
and	O	O
the	O	O
mixed	O	O
lymphocyte	O	O
reaction	O	O
.	O	O

Studies	O	O
were	O	O
repeated	O	O
with	O	O
PBMCs	O	O
from	O	O
six	O	O
individuals	O	O
using	O	O
a	O	O
GH	O	O
dose	O	O
of	O	O
100	O	O
ng/mL	O	O
(	O	O
the	O	O
level	O	O
of	O	O
GH	O	O
found	O	O
after	O	O
high-dose	O	O
GH	O	O
therapy	B-protein	O
)	O	O
and	O	O
an	O	O
endotoxin	O	O
dose	O	O
that	O	O
gave	O	O
a	O	O
submaximal	O	O
response	O	O
(	O	O
0.01	O	O
ng/mL	O	O
)	O	O
.	O	O

GH	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
cell	O	O
proliferation	O	O
or	O	O
the	O	O
production	O	O
of	O	O
tumor	B-protein	O
necrosis	I-protein	O
factor-alpha	I-protein	O
(	O	O
TNFalpha	B-protein	O
)	I-protein	O
,	O	O
interleukin-6	B-protein	O
(	O	O
IL-6	I-protein	O
)	O	O
,	O	O
or	O	O
interferon-gamma	O	O
(	O	O
IFNgamma	O	O
)	O	O
.	O	O

In	O	O
patients	O	O
undergoing	O	O
laparoscopic	O	O
cholecystectomy	O	O
there	O	O
was	O	O
a	O	O
time-related	O	O
effect	O	O
of	O	O
surgery	O	O
on	O	O
cytokine	B-protein	O
levels	O	O
.	O	O

There	O	O
was	O	O
a	O	O
rise	O	O
in	O	O
IL-6	O	O
and	O	O
a	O	O
fall	O	O
in	O	O
TNFalpha	O	O
at	O	O
24	O	O
h	O	O
after	O	O
surgery	O	O
;	O	O
however	O	O
,	O	O
high-dose	O	O
GH	O	O
therapy	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
cytokine	O	O
response	O	O
.	O	O

We	O	O
considered	O	O
the	O	O
possibility	O	O
that	O	O
endogenous	O	O
GH	O	O
production	O	O
by	O	O
PBMCs	O	O
could	O	O
influence	O	O
the	O	O
cytokine	O	O
response	O	O
in	O	O
activated	O	O
PBMCs	O	O
;	O	O
however	O	O
,	O	O
incubation	O	O
of	O	O
PBMCs	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
GH	B-protein	O
receptor	I-protein	O
antagonist	O	O
,	O	O
B2036	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
TNFalpha	B-protein	O
,	O	O
IL-6	O	O
,	O	O
or	O	O
IFNgamma	O	O
production	O	O
by	O	O
PBMCs	O	O
in	O	O
either	O	O
the	O	O
mixed	O	O
lymphocyte	O	O
reaction	O	O
or	O	O
when	O	O
activated	O	O
by	O	O
endotoxin	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
high-dose	O	O
GH	O	O
therapy	O	O
does	O	O
not	O	O
alter	O	O
the	O	O
proinflammatory	O	O
cytokine	O	O
response	O	O
to	O	O
surgery	O	O
or	O	O
endotoxin	O	O
.	O	O

The	O	O
results	O	O
do	O	O
not	O	O
exclude	O	O
an	O	O
effect	O	O
of	O	O
GH	O	O
on	O	O
the	O	O
immune	O	O
response	O	O
,	O	O
but	O	O
they	O	O
suggest	O	O
that	O	O
the	O	O
mortality	O	O
seen	O	O
in	O	O
critically	O	O
ill	O	O
patients	O	O
may	O	O
be	O	O
due	O	O
to	O	O
factors	B-protein	O
other	O	O
than	O	O
immune	O	O
modulation	O	O
.	O	O

Interaction	O	O
between	O	O
interferon	O	O
consensus	B-protein	O
sequence-binding	I-protein	O
protein	I-protein	O
and	O	O
COP9/signalosome	O	O
subunit	O	O
CSN2	O	O
(	O	O
Trip15	O	O
)	O	O
.	O	O

A	O	O
possible	O	O
link	O	O
between	O	O
interferon	B-protein	O
regulatory	I-protein	O
factor	I-protein	O
signaling	O	O
and	O	O
the	O	O
COP9/signalosome	O	O
.	O	O

Interferon	B-protein	O
consensus	I-protein	O
sequence-binding	I-protein	O
protein	I-protein	O
(	O	O
ICSBP	B-protein	O
)	O	O
is	O	O
a	O	O
member	O	O
of	O	O
the	O	O
interferon	B-protein	O
regulatory	I-protein	O
factors	I-protein	O
(	O	O
IRF	B-protein	O
)	O	O
that	O	O
has	O	O
a	O	O
pivotal	O	O
role	O	O
in	O	O
mediating	O	O
resistance	O	O
to	O	O
pathogenic	O	O
infections	O	O
in	O	O
mice	O	O
and	O	O
in	O	O
promoting	O	O
the	O	O
differentiation	O	O
of	O	O
myeloid	B-cell_type	O
cells	I-cell_type	O
.	O	O

ICSBP	O	O
exerts	O	O
some	O	O
of	O	O
its	O	O
transcriptional	O	O
activities	O	O
via	O	O
association	O	O
with	O	O
other	O	O
factors	I-protein	O
that	O	O
enable	O	O
its	O	O
binding	O	O
to	O	O
a	O	O
variety	O	O
of	O	O
promoters	B-DNA	O
containing	O	O
DNA	B-DNA	O
composite	I-DNA	O
elements	I-DNA	O
.	O	O

These	O	O
interactions	O	O
are	O	O
mediated	O	O
through	O	O
a	O	O
specific	O	O
COOH-terminal	O	O
domain	O	O
termed	O	O
IAD	O	O
(	O	O
IRF	O	O
association	I-protein	O
domain	I-protein	O
)	O	O
.	O	O

To	O	O
gain	O	O
a	O	O
broader	O	O
insight	O	O
of	O	O
the	O	O
capacity	O	O
of	O	O
ICSBP	O	O
to	O	O
interact	O	O
with	O	O
other	B-protein	O
factors	I-protein	O
,	O	O
yeast	O	O
two-hybrid	O	O
screens	O	O
were	O	O
performed	O	O
using	O	O
ICSBP-IAD	O	O
as	O	O
a	O	O
bait	O	O
against	O	O
a	O	O
B-cell	O	O
cDNA	O	O
library	O	O
.	O	O

Trip15	O	O
was	O	O
identified	O	O
as	O	O
a	O	O
specific	O	O
interacting	B-protein	O
factor	I-protein	O
with	O	O
ICSBP	O	O
in	O	O
yeast	B-cell_type	O
cells	I-cell_type	O
,	O	O
which	O	O
was	O	O
also	O	O
confirmed	O	O
by	O	O
in	O	O
vitro	O	O
glutathione	O	O
S-transferase	O	O
pull-down	O	O
assays	O	O
and	O	O
by	O	O
coimmunoprecipitation	O	O
studies	O	O
in	O	O
COS7	B-cell_type	O
cells	I-cell_type	O
.	O	O

Trip15	O	O
was	O	O
recently	O	O
identified	O	O
as	O	O
a	O	O
component	O	O
of	O	O
the	O	O
COP9/signalosome	B-protein	O
(	I-protein	O
CSN	I-protein	O
)	I-protein	O
complex	I-protein	O
composed	O	O
of	O	O
eight	O	O
evolutionary	O	O
conserved	O	O
subunits	B-protein	O
and	O	O
thus	O	O
termed	O	O
CSN2	O	O
.	O	O

This	O	O
complex	O	O
has	O	O
a	O	O
role	O	O
in	O	O
cell-signaling	O	O
processes	O	O
,	O	O
which	O	O
is	O	O
manifested	O	O
by	O	O
its	O	O
associated	O	O
novel	O	O
kinase	O	O
activity	O	O
and	O	O
by	O	O
the	O	O
involvement	O	O
of	O	O
its	O	O
subunits	B-protein	O
in	O	O
regulating	O	O
multiple	O	O
cell-signaling	O	O
pathways	O	O
and	O	O
cell-cycle	O	O
progression	O	O
.	O	O

We	O	O
show	O	O
that	O	O
in	O	O
vitro	O	O
association	O	O
of	O	O
ICSBP	O	O
with	O	O
the	O	O
CSN	O	O
leads	O	O
to	O	O
phosphorylation	O	O
of	O	O
ICSBP	O	O
at	O	O
a	O	O
unique	O	O
serine	O	O
residue	O	O
within	O	O
its	O	O
IAD	O	O
.	O	O

The	O	O
phosphorylated	O	O
residue	O	O
is	O	O
essential	O	O
for	O	O
efficient	O	O
association	O	O
with	O	O
IRF-1	O	O
and	O	O
thus	O	O
for	O	O
the	O	O
repressor	O	O
activity	O	O
of	O	O
ICSBP	O	O
exerted	O	O
on	O	O
IRF-1	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
the	O	O
CSN	O	O
has	O	O
a	O	O
role	O	O
in	O	O
integrating	O	O
incoming	O	O
signals	O	O
that	O	O
affect	O	O
the	O	O
transcriptional	O	O
activity	O	O
of	O	O
ICSBP	O	O
.	O	O

Intrathymic	O	O
T	O	O
cell	O	O
development	O	O
and	O	O
selection	O	O
proceeds	O	O
normally	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
glucocorticoid	B-protein	O
receptor	I-protein	O
signaling	O	O
.	O	O

Glucocorticoids	O	O
are	O	O
believed	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
T	O	O
cell	O	O
development	O	O
and	O	O
selection	O	O
,	O	O
although	O	O
their	O	O
precise	O	O
function	O	O
is	O	O
controversial	O	O
.	O	O

Glucocorticoid	B-protein	O
receptor	I-protein	O
(	O	O
GR	B-protein	O
)	O	O
-deficient	O	O
mice	O	O
were	O	O
used	O	O
to	O	O
directly	O	O
investigate	O	O
this	O	O
problem	O	O
.	O	O

GR-deficient	O	O
thymocytes	O	O
were	O	O
resistant	O	O
to	O	O
dexamethasone-mediated	O	O
apoptosis	O	O
,	O	O
confirming	O	O
the	O	O
absence	O	O
of	O	O
glucocorticoid	O	O
responsiveness	O	O
.	O	O

An	O	O
absence	O	O
of	O	O
GR	B-protein	O
signaling	O	O
had	O	O
no	O	O
impact	O	O
on	O	O
thymocyte	O	O
development	O	O
either	O	O
in	O	O
vivo	O	O
or	O	O
in	O	O
vitro	O	O
.	O	O

T	O	O
cell	O	O
differentiation	O	O
,	O	O
including	O	O
positive	O	O
selection	O	O
,	O	O
was	O	O
normal	O	O
as	O	O
assessed	O	O
by	O	O
normal	O	O
development	O	O
of	O	O
CD4+CD8+	O	O
,	O	O
alphabetaTCR+CD4+	O	O
,	O	O
and	O	O
alphabetaTCR+CD8+	O	O
thymocytes	B-cell_type	O
.	O	O

Negative	O	O
selection	O	O
,	O	O
mediated	O	O
by	O	O
the	O	O
superantigen	B-protein	O
staphylococcal	I-protein	O
enterotoxin	I-protein	O
B	I-protein	O
(	O	O
SEB	B-protein	O
)	O	O
,	O	O
or	O	O
anti-CD3/CD28	O	O
,	O	O
was	O	O
also	O	O
normal	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
GR	O	O
signaling	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
earlier	O	O
reports	O	O
,	O	O
these	O	O
data	O	O
demonstrate	O	O
that	O	O
GR	O	O
signaling	O	O
is	O	O
not	O	O
essential	O	O
for	O	O
intrathymic	O	O
T	O	O
cell	O	O
development	O	O
or	O	O
selection	O	O
.	O	O

Rapid	O	O
polarization	O	O
of	O	O
Th2	B-cell_type	O
cells	I-cell_type	O
during	O	O
induction	O	O
of	O	O
antigen-specific	O	O
IgE	O	O
antibodies	O	O
in	O	O
vitro	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Type	O	O
2	O	O
T-helper	B-cell_type	O
cells	I-cell_type	O
(	O	O
Th2	O	O
)	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
the	O	O
humoral	O	O
immune	O	O
response	O	O
against	O	O
antigens	O	O
and	O	O
allergens	O	O
and	O	O
directly	O	O
affect	O	O
which	O	O
isotype	O	O
will	O	O
be	O	O
produced	O	O
.	O	O

The	O	O
mechanism	O	O
that	O	O
regulates	O	O
antigen-specific	O	O
IgE	O	O
secretion	O	O
and	O	O
immune	O	O
deviation	O	O
is	O	O
still	O	O
not	O	O
known	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
delineate	O	O
mechanisms	O	O
behind	O	O
antigen-specific	O	O
IgE	O	O
secretion	O	O
we	O	O
have	O	O
used	O	O
in	O	O
vitro	O	O
immunization	O	O
and	O	O
focused	O	O
on	O	O
T-cell	O	O
phenotype	O	O
and	O	O
the	O	O
activation	O	O
status	O	O
of	O	O
the	O	O
transcription	B-protein	O
factor	I-protein	O
NFkappaB	O	O
.	O	O

METHODS	O	O
:	O	O
Peripheral	B-cell_type	O
blood	I-cell_type	O
lymphocytes	I-cell_type	O
(	O	O
PBMC	O	O
)	O	O
from	O	O
seronegative	O	O
donors	O	O
were	O	O
immunized	O	O
in	O	O
vitro	O	O
with	O	O
a	O	O
peptide	O	O
consisting	O	O
of	O	O
both	O	O
a	O	O
T-cell	O	O
and	O	O
a	O	O
B-cell	O	O
epitope	O	O
.	O	O

RESULTS	O	O
:	O	O
Antigen-specific	O	O
IgE	O	O
antibodies	O	O
could	O	O
be	O	O
detected	O	O
after	O	O
a	O	O
primary	O	O
immunization	O	O
,	O	O
during	O	O
which	O	O
T-helper	O	O
cells	O	O
secreted	O	O
type	O	O
2	O	O
cytokines	O	O
.	O	O

Specific	O	O
IgE	O	O
was	O	O
also	O	O
detected	O	O
in	O	O
the	O	O
secondary	O	O
immunization	O	O
,	O	O
but	O	O
due	O	O
to	O	O
a	O	O
rapid	O	O
polarization	O	O
from	O	O
Th2	O	O
to	O	O
Th1	O	O
phenotype	O	O
,	O	O
exogenous	O	O
IL-4	O	O
was	O	O
required	O	O
for	O	O
the	O	O
specific	O	O
IgE	O	O
secretion	O	O
.	O	O

Analysis	O	O
of	O	O
NFkappaB	O	O
activation	O	O
in	O	O
B	B-cell_type	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
during	O	O
primary	O	O
and	O	O
secondary	O	O
immunization	O	O
showed	O	O
that	O	O
NFkappaB	O	O
could	O	O
be	O	O
detected	O	O
in	O	O
both	O	O
B	O	O
and	O	O
T	B-cell_type	O
cells	I-cell_type	O
during	O	O
primary	O	O
immunization	O	O
,	O	O
but	O	O
was	O	O
dependent	O	O
on	O	O
exogenous	O	O
IL-4	O	O
in	O	O
the	O	O
secondary	O	O
immunization	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
evidence	O	O
of	O	O
antigen-specific	O	O
IgE	O	O
induction	O	O
in	O	O
vitro	O	O
using	O	O
naive	B-cell_type	O
B	I-cell_type	O
cells	I-cell_type	O
,	O	O
demonstrating	O	O
the	O	O
involvement	O	O
of	O	O
T-helper	O	O
cell	O	O
phenotype	O	O
and	O	O
NFkappaB	O	O
and	O	O
demonstrates	O	O
the	O	O
usefulness	O	O
of	O	O
in	O	O
vitro	O	O
cultures	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
antigens	O	O
on	O	O
human	O	O
immunocytes	O	O
.	O	O

Pulmonary	O	O
function	O	O
changes	O	O
and	O	O
increased	O	O
Th-2	O	O
cytokine	B-protein	O
expression	O	O
and	O	O
nuclear	B-protein	O
factor	I-protein	O
kB	O	O
activation	O	O
in	O	O
the	O	O
lung	O	O
after	O	O
sensitization	O	O
and	O	O
allergen	O	O
challenge	O	O
in	O	O
brown	O	O
Norway	O	O
rats	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Our	O	O
purpose	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
expression	O	O
of	O	O
Th-1	O	O
and	O	O
Th-2	O	O
related	O	O
cytokine	B-protein	O
mRNA	I-RNA	O
and	O	O
nuclear	B-protein	O
factor	I-protein	O
(	O	O
NF	B-protein	O
)	O	O
kB	O	O
in	O	O
the	O	O
lung	O	O
tissue	O	O
of	O	O
ovalbumin	O	O
(	O	O
OA	O	O
)	O	O
sensitized	O	O
brown	O	O
Norway	O	O
rats	O	O
(	O	O
BNR	O	O
)	O	O
.	O	O

We	O	O
also	O	O
evaluated	O	O
the	O	O
correlation	O	O
between	O	O
bronchial	O	O
hyperreactivity	O	O
(	O	O
BHR	O	O
)	O	O
and	O	O
eosinophils	O	O
with	O	O
cytokine	O	O
mRNA	O	O
expression	O	O
.	O	O

METHODS	O	O
:	O	O
Eight	O	O
BNR	O	O
(	O	O
weight	O	O
range	O	O
250-350	O	O
g	O	O
)	O	O
were	O	O
sensitized	O	O
by	O	O
inhaled	O	O
OA	O	O
(	O	O
group	O	O
I	O	O
)	O	O
with	O	O
a	O	O
1-week	O	O
interval	O	O
between	O	O
and	O	O
then	O	O
provoked	O	O
with	O	O
OA	O	O
1	O	O
week	O	O
later	O	O
.	O	O

Pulmonary	O	O
function	O	O
tests	O	O
(	O	O
PFT	O	O
)	O	O
were	O	O
performed	O	O
at	O	O
baseline	O	O
and	O	O
24	O	O
h	O	O
after	O	O
acetylcholine	O	O
challenge	O	O
.	O	O

Eight	O	O
weight-matched	O	O
normal	O	O
BNR	O	O
served	O	O
as	O	O
controls	O	O
(	O	O
group	O	O
II	O	O
)	O	O
.	O	O

All	O	O
animals	O	O
were	O	O
anesthetized	O	O
,	O	O
paralyzed	O	O
with	O	O
gallamine	O	O
,	O	O
and	O	O
ventilated	O	O
via	O	O
tracheostomy	O	O
.	O	O

They	O	O
were	O	O
given	O	O
varying	O	O
doses	O	O
of	O	O
acetylcholine	O	O
(	O	O
25	O	O
,	O	O
50	O	O
,	O	O
75	O	O
,	O	O
100	O	O
microg/kg	O	O
)	O	O
injected	O	O
through	O	O
a	O	O
jugular	O	O
venous	O	O
catheter	O	O
.	O	O

Five	O	O
seconds	O	O
after	O	O
acetylcholine	O	O
injections	O	O
,	O	O
PFTs	O	O
were	O	O
performed	O	O
,	O	O
including	O	O
a	O	O
maximal	O	O
forced	O	O
expiratory	O	O
maneuver	O	O
(	O	O
MFEM	O	O
)	O	O
,	O	O
airway	O	O
opening	O	O
pressure	O	O
(	O	O
P	O	O
(	O	O
ao	O	O
)	O	O
)	O	O
at	O	O
tidal	O	O
breathing	O	O
and	O	O
total	O	O
dynamic	O	O
lung	O	O
compliance	O	O
(	O	O
C	O	O
(	O	O
dyn	O	O
)	O	O
)	O	O
.	O	O

Bronchoalveolar	O	O
lavage	O	O
(	O	O
BAL	O	O
)	O	O
was	O	O
then	O	O
performed	O	O
with	O	O
20	O	O
ml	O	O
normal	O	O
saline	O	O
divided	O	O
into	O	O
two	O	O
doses	O	O
.	O	O

Thereafter	O	O
,	O	O
the	O	O
lungs	O	O
were	O	O
removed	O	O
and	O	O
examined	O	O
histologically	O	O
.	O	O

Total	O	O
RNA	O	O
was	O	O
extracted	O	O
from	O	O
lung	O	O
tissue	O	O
samples	O	O
and	O	O
reverse-transcriptase	O	O
polymerase	O	O
chain	O	O
reaction	O	O
was	O	O
performed	O	O
using	O	O
primers	O	O
for	O	O
mRNA	O	O
of	O	O
IL-4	B-protein	O
,	O	O
IL-5	B-protein	O
,	O	O
IL-10	B-protein	O
,	O	O
interferon-gamma	O	O
(	O	O
IFNr	B-protein	O
)	O	O
and	O	O
beta-actine	O	O
.	O	O

RESULTS	O	O
:	O	O
Group	O	O
I	O	O
OA	O	O
treated	O	O
rats	O	O
had	O	O
typical	O	O
airway	O	O
obstruction	O	O
on	O	O
PFTs	O	O
and	O	O
airway	O	O
inflammation	O	O
on	O	O
histological	O	O
examination	O	O
.	O	O

Ratios	O	O
of	O	O
IL-4	B-protein	O
,	O	O
IL-5	B-protein	O
,	O	O
IL-10	B-protein	O
and	O	O
inducible	O	O
nitric	O	O
oxide	O	O
synthase	O	O
(	O	O
iNOS	O	O
)	O	O
mRNA	O	O
levels	O	O
to	O	O
beta-actine	O	O
as	O	O
measured	O	O
by	O	O
densitometry	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
controls	O	O
than	O	O
in	O	O
OA-sensitized	O	O
rats	O	O
.	O	O

The	O	O
IFNr	O	O
mRNA	I-RNA	O
to	O	O
beta-actin	O	O
ratio	O	O
was	O	O
significantly	O	O
reduced	O	O
in	O	O
OA-sensitized	O	O
rats	O	O
.	O	O

Group	O	O
I	O	O
demonstrated	O	O
a	O	O
band	O	O
shift	O	O
when	O	O
compared	O	O
with	O	O
group	O	O
II	O	O
in	O	O
electromobility	O	O
shift	O	O
assay	O	O
(	O	O
EMSA	O	O
)	O	O
for	O	O
NF-kB	O	O
indicating	O	O
increased	O	O
activation	O	O
of	O	O
this	O	O
transcription	B-protein	O
factor	I-protein	O
.	O	O

CONCLUSION	O	O
:	O	O
Th-2	O	O
related	O	O
cytokine	O	O
mRNA	O	O
was	O	O
increased	O	O
but	O	O
Th-1	O	O
related	O	O
cytokine	O	O
mRNA	I-RNA	O
was	O	O
decreased	O	O
in	O	O
OA-sensitized	O	O
BNR	O	O
.	O	O

An	O	O
increased	O	O
level	O	O
of	O	O
Th-2	O	O
related	O	O
cytokine	O	O
mRNA	I-RNA	O
correlated	O	O
with	O	O
decreased	O	O
airflow	O	O
and	O	O
inflammatory	O	O
changes	O	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
the	O	O
value	O	O
of	O	O
the	O	O
BNR	O	O
model	O	O
for	O	O
studying	O	O
allergic	O	O
asthma	O	O
at	O	O
the	O	O
molecular	O	O
level	O	O
.	O	O

3	O	O
,	O	O
5-Bis	O	O
(	O	O
trifluoromethyl	B-protein	O
)	O	O
pyrazoles	O	O
:	O	O
a	O	O
novel	O	O
class	O	O
of	O	O
NFAT	B-protein	O
transcription	B-protein	O
factor	I-protein	O
regulator	O	O
.	O	O

A	O	O
series	O	O
of	O	O
bis	O	O
(	O	O
trifluoromethyl	B-protein	O
)	O	O
pyrazoles	O	O
(	O	O
BTPs	O	O
)	O	O
has	O	O
been	O	O
found	O	O
to	O	O
be	O	O
a	O	O
novel	O	O
inhibitor	O	O
of	O	O
cytokine	B-protein	O
production	O	O
.	O	O

Identified	O	O
initially	O	O
as	O	O
inhibitors	O	O
of	O	O
IL-2	B-protein	O
synthesis	O	O
,	O	O
the	O	O
BTPs	O	O
have	O	O
been	O	O
optimized	O	O
in	O	O
this	O	O
regard	O	O
and	O	O
even	O	O
inhibit	O	O
IL-2	B-protein	O
production	O	O
with	O	O
a	O	O
10-fold	O	O
enhancement	O	O
over	O	O
cyclosporine	O	O
in	O	O
an	O	O
ex	O	O
vivo	O	O
assay	O	O
.	O	O

Additionally	O	O
,	O	O
the	O	O
BTPs	O	O
show	O	O
inhibition	O	O
of	O	O
IL-4	B-protein	O
,	O	O
IL-5	B-protein	O
,	O	O
IL-8	O	O
,	O	O
and	O	O
eotaxin	O	O
production	O	O
.	O	O

Unlike	O	O
the	O	O
IL-2	B-protein	O
inhibitors	O	O
,	O	O
cyclosporine	O	O
and	O	O
FK506	O	O
,	O	O
the	O	O
BTPs	O	O
do	O	O
not	O	O
directly	O	O
inhibit	O	O
the	O	O
dephosphorylation	O	O
of	O	O
NFAT	B-protein	O
by	O	O
calcineurin	B-protein	O
.	O	O

A	O	O
repression-derepression	O	O
mechanism	O	O
regulating	O	O
the	O	O
transcription	O	O
of	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
in	O	O
primary	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

BACKGROUND	O	O
:	O	O
Despite	O	O
some	O	O
controversy	O	O
regarding	O	O
the	O	O
preferential	O	O
infection	O	O
and	O	O
replication	O	O
of	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HIV-1	O	O
)	O	O
,	O	O
it	O	O
appears	O	O
that	O	O
primary	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
in	O	O
their	O	O
quiescent	O	O
state	O	O
,	O	O
are	O	O
nonpermissive	O	O
for	O	O
viral	O	O
expression	O	O
and	O	O
propagation	O	O
.	O	O

Massive	O	O
activation	O	O
of	O	O
viral	B-DNA	O
gene	I-DNA	O
expression	O	O
occurs	O	O
only	O	O
when	O	O
the	O	O
host	O	O
lymphocyte	O	O
is	O	O
activated	O	O
.	O	O

These	O	O
observations	O	O
prompted	O	O
us	O	O
to	O	O
investigate	O	O
the	O	O
transcriptional	O	O
regulation	O	O
of	O	O
HIV-1	O	O
in	O	O
resting	O	O
or	O	O
activated	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
that	O	O
were	O	O
isolated	O	O
from	O	O
cord	O	O
blood	O	O
or	O	O
adult	O	O
peripheral	O	O
blood	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
To	O	O
this	O	O
end	O	O
,	O	O
we	O	O
employed	O	O
cellular	O	O
purification	O	O
and	O	O
phenotyping	O	O
techniques	O	O
,	O	O
in	O	O
vitro	O	O
protein-DNA	O	O
binding	O	O
studies	O	O
,	O	O
functional	O	O
transactivation	O	O
assays	B-protein	O
using	I-protein	O
proteins	I-protein	O
isolated	O	O
from	O	O
cord	B-cell_line	O
blood	I-cell_line	O
or	O	O
adult	B-cell_type	O
peripheral	I-cell_type	O
blood	I-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
,	O	O
and	O	O
transfection	O	O
experiments	O	O
in	O	O
primary	B-cell_type	O
T	I-cell_type	O
cells	I-cell_type	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
showed	O	O
that	O	O
transcription	O	O
from	O	O
the	O	O
HIV-1	O	O
long	O	O
terminal	O	O
repeat	O	O
is	O	O
repressed	O	O
in	O	O
resting	O	O
naive	O	O
T	B-cell_type	O
lymphocytes	I-cell_type	O
;	O	O
whereas	O	O
,	O	O
mitogenically	O	O
stimulated	O	O
CD4+	O	O
cells	O	O
form	O	O
an	O	O
activator	O	O
that	O	O
derepresses	O	O
transcription	O	O
.	O	O

Negative	O	O
and	O	O
positive	O	O
regulation	O	O
act	O	O
through	O	O
a	O	O
repressor-activator	O	O
target	O	O
sequence	O	O
(	O	O
RATS	O	O
)	O	O
,	O	O
which	O	O
shares	O	O
homology	O	O
with	O	O
the	O	O
interleukin-2	B-protein	O
(	O	O
IL-2	B-protein	O
)	O	O
purine-rich	O	O
response	O	O
element	O	O
,	O	O
through	O	O
the	O	O
adjacent	O	O
binding	I-DNA	O
site	I-DNA	O
of	O	O
the	O	O
nuclear	B-protein	O
factor	I-protein	O
of	I-protein	O
activated	I-protein	O
T	I-protein	O
cells	I-protein	O
(	O	O
NFAT	B-protein	O
)	O	O
,	O	O
and	O	O
weakly	O	O
,	O	O
through	O	O
the	O	O
KB	O	O
region	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
regulation	O	O
exerted	O	O
by	O	O
cellular	O	O
transcription	B-protein	O
factors	I-protein	O
can	O	O
account	O	O
for	O	O
several	O	O
important	O	O
features	O	O
of	O	O
HIV-1	O	O
expression	O	O
in	O	O
primary	B-cell_line	O
CD4+	I-cell_line	O
cells	I-cell_line	O
.	O	O

Tight	O	O
repression	O	O
in	O	O
resting	O	O
naive	B-cell_line	O
T	I-cell_line	O
helper	I-cell_line	O
cells	I-cell_type	O
may	O	O
be	O	O
a	O	O
main	O	O
cause	O	O
of	O	O
viral	O	O
latency	O	O
and	O	O
transcriptional	O	O
activation	O	O
accounts	O	O
for	O	O
massive	O	O
viral	O	O
production	O	O
in	O	O
activated	B-cell_type	O
T	I-cell_type	O
lymphocytes	I-cell_type	O
.	O	O

Involvement	O	O
of	O	O
lipopolysaccharide	B-protein	O
binding	I-protein	O
protein	I-protein	O
,	O	O
CD14	O	O
,	O	O
and	O	O
Toll-like	O	O
receptors	O	O
in	O	O
the	O	O
initiation	O	O
of	O	O
innate	O	O
immune	O	O
responses	O	O
by	O	O
Treponema	O	O
glycolipids	O	O
.	O	O

Culture	O	O
supernatants	O	O
from	O	O
Treponema	O	O
maltophilum	O	O
associated	O	O
with	O	O
periodontitis	O	O
in	O	O
humans	O	O
and	O	O
Treponema	O	O
brennaborense	O	O
found	O	O
in	O	O
a	O	O
bovine	O	O
cattle	O	O
disease	O	O
accompanied	O	O
with	O	O
cachexia	O	O
caused	O	O
a	O	O
dose-dependent	O	O
TNF-alpha	O	O
synthesis	O	O
in	O	O
human	B-cell_type	O
monocytes	I-cell_type	O
increasing	O	O
with	O	O
culture	O	O
time	O	O
.	O	O

This	O	O
activity	O	O
could	O	O
be	O	O
reduced	O	O
significantly	O	O
by	O	O
blocking	O	O
the	O	O
CD14	O	O
-part	O	O
of	O	O
the	O	O
LPS	B-protein	O
receptor	I-protein	O
using	O	O
the	O	O
My	B-protein	O
4	I-protein	O
mAb	I-protein	O
and	O	O
by	O	O
polymyxin	B-protein	O
B	I-protein	O
.	O	O

In	O	O
the	O	O
murine	O	O
macrophage	O	O
cell	O	O
line	O	O
RAW	O	O
264.7	O	O
,	O	O
Treponema	O	O
culture	O	O
supernatants	O	O
induced	O	O
TNF-alpha	O	O
secretion	O	O
in	O	O
a	O	O
LPS	O	O
binding	O	O
protein	O	O
(	O	O
LBP	O	O
)	O	O
-dependent	O	O
fashion	O	O
.	O	O

To	O	O
enrich	O	O
for	O	O
active	O	O
compounds	O	O
,	O	O
supernatants	O	O
were	O	O
extracted	O	O
with	O	O
butanol	O	O
,	O	O
while	O	O
whole	O	O
cells	O	O
were	O	O
extracted	O	O
using	O	O
a	O	O
phenol/water	O	O
method	O	O
resulting	O	O
in	O	O
recovery	O	O
of	O	O
material	O	O
exhibiting	O	O
a	O	O
similar	O	O
activity	O	O
profile	O	O
.	O	O

An	O	O
LPS-LBP	O	O
binding	O	O
competition	O	O
assay	O	O
revealed	O	O
an	O	O
interaction	O	O
of	O	O
the	O	O
treponeme	O	O
phenol/water	O	O
extracts	O	O
with	O	O
LBP	O	O
,	O	O
while	O	O
precipitation	O	O
studies	O	O
implied	O	O
an	O	O
affinity	O	O
to	O	O
polymyxin	O	O
B	I-protein	O
and	O	O
endotoxin	O	O
neutralizing	B-protein	O
protein	I-protein	O
.	O	O

Macrophages	O	O
obtained	O	O
from	O	O
C3H/HeJ	O	O
mice	O	O
carrying	O	O
a	O	O
Toll-like	B-protein	O
receptor	I-protein	O
(	O	O
TLR	O	O
)	O	O
-4	O	O
mutation	O	O
were	O	O
stimulated	O	O
with	O	O
treponeme	O	O
extracts	O	O
for	O	O
NO	O	O
release	O	O
to	O	O
assess	O	O
the	O	O
role	O	O
of	O	O
TLRs	O	O
in	O	O
cell	O	O
activation	O	O
.	O	O

Furthermore	O	O
,	O	O
NF-kappaB	O	O
translocation	O	O
in	O	O
TLR-2-negative	O	O
Chinese	O	O
hamster	I-cell_line	O
ovary	I-cell_line	O
(	I-cell_line	O
CHO	I-cell_line	O
)	I-cell_line	O
cells	I-cell_line	O
was	O	O
studied	O	O
.	O	O

We	O	O
found	O	O
that	O	O
phenol/water-extracts	O	O
of	O	O
the	O	O
two	O	O
strains	O	O
use	O	O
TLRs	O	O
differently	O	O
with	O	O
T.	O	O
brennaborense-stimulating	O	O
cells	O	O
in	O	O
a	O	O
TLR-4-dependent	O	O
fashion	O	O
,	O	O
while	O	O
T.	O	O
maltophilum-mediated	O	O
activation	O	O
apparently	O	O
involved	O	O
TLR-2	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
novel	O	O
class	O	O
of	O	O
glycolipids	O	O
in	O	O
Treponema	O	O
initiating	O	O
inflammatory	O	O
responses	O	O
involving	O	O
LBP	O	O
,	O	O
CD14	O	O
,	O	O
and	O	O
TLRs	O	O
.	O	O

Integration	O	O
of	O	O
calcineurin	B-protein	O
and	O	O
MEF2	O	O
signals	O	O
by	O	O
the	O	O
coactivator	O	O
p300	O	O
during	O	O
T-cell	O	O
apoptosis	O	O
.	O	O

T-cell	B-protein	O
antigen	I-protein	O
receptor	I-protein	O
(	O	O
TCR	B-protein	O
)	O	O
-induced	O	O
thymocyte	O	O
apoptosis	O	O
is	O	O
mediated	O	O
by	O	O
calcium-dependent	O	O
signal	O	O
transduction	O	O
pathways	O	O
leading	O	O
to	O	O
the	O	O
transcriptional	O	O
activation	O	O
of	O	O
members	O	O
of	O	O
the	O	O
Nur77	B-protein	O
family	I-protein	O
.	O	O

The	O	O
major	B-DNA	O
calcium-	I-DNA	O
and	I-DNA	O
calcineurin-responsive	I-DNA	O
elements	I-DNA	O
in	O	O
the	O	O
Nur77	B-DNA	O
promoter	I-DNA	O
are	O	O
binding	O	O
sites	O	O
for	O	O
myocyte	B-DNA	O
enhancer	I-DNA	O
factor-2	O	O
(	O	O
MEF2	B-protein	O
)	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
nuclear	B-protein	O
factor	I-protein	O
of	O	O
activated	I-protein	O
T	I-protein	O
cells	I-protein	O
(	O	O
NFAT	B-protein	O
)	O	O
interacts	O	O
with	O	O
MEF2D	O	O
and	O	O
enhances	O	O
its	O	O
transcriptional	O	O
activity	O	O
,	O	O
offering	O	O
a	O	O
plausible	O	O
mechanism	O	O
of	O	O
activation	O	O
of	O	O
MEF2D	O	O
by	O	O
calcineurin	B-protein	O
.	O	O

We	O	O
report	O	O
here	O	O
that	O	O
NFATp	O	O
synergizes	O	O
with	O	O
MEF2D	O	O
to	O	O
recruit	O	O
the	O	O
coactivator	O	O
p300	O	O
for	O	O
the	O	O
transcription	O	O
of	O	O
Nur77	O	O
.	O	O

Surprisingly	O	O
,	O	O
the	O	O
enhancement	O	O
of	O	O
transcriptional	O	O
activity	O	O
of	O	O
MEF2D	O	O
by	O	O
NFATp	O	O
does	O	O
not	O	O
require	O	O
its	O	O
DNA-binding	O	O
activity	O	O
,	O	O
suggesting	O	O
that	O	O
NFATp	O	O
acts	O	O
as	O	O
a	O	O
coactivator	O	O
for	O	O
MEF2D	O	O
.	O	O

Transient	O	O
co-expression	O	O
of	O	O
p300	B-protein	O
,	O	O
MEF2D	O	O
,	O	O
NFATp	O	O
and	O	O
constitutively	O	O
active	O	O
calcineurin	O	O
is	O	O
sufficient	O	O
to	O	O
recapitulate	O	O
TCR	B-protein	O
signaling	O	O
for	O	O
the	O	O
selective	O	O
induction	O	O
of	O	O
the	O	O
endogenous	B-DNA	O
Nur77	I-DNA	O
gene	I-DNA	O
.	O	O

These	O	O
results	O	O
implicate	O	O
NFAT	B-protein	O
as	O	O
an	O	O
important	O	O
mediator	O	O
of	O	O
T-cell	O	O
apoptosis	O	O
and	O	O
suggest	O	O
that	O	O
NFAT	B-protein	O
is	O	O
capable	O	O
of	O	O
integrating	O	O
the	O	O
calcineurin	B-protein	O
signaling	O	O
pathway	O	O
and	O	O
other	O	O
pathways	O	O
through	O	O
direct	O	O
protein-protein	O	O
interaction	O	O
with	O	O
other	O	O
transcription	B-protein	O
factors	I-protein	O
.	O	O

Induction	O	O
or	O	O
suppression	O	O
of	O	O
a	O	O
B	B-DNA	O
cell-specific	I-DNA	O
response	O	O
to	O	O
self	O	O
antigen	O	O
in	O	O
vivo	O	O
is	O	O
dependent	O	O
upon	O	O
dendritic	O	O
cell	O	O
activation	O	O
via	O	O
the	O	O
TNF-alpha	B-protein	O
receptor	I-protein	O
at	O	O
the	O	O
time	O	O
of	O	O
antigen	O	O
uptake	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
show	O	O
that	O	O
the	O	O
retinal	O	O
autoantigen	O	O
,	O	O
S-antigen	O	O
,	O	O
contains	O	O
a	O	O
functional	O	O
TNF-alpha	O	O
homologous	O	O
domain	O	O
which	O	O
stimulates	O	O
maturation	O	O
and	O	O
differentiation	O	O
of	O	O
cultured	B-cell_line	O
dendritic	I-cell_line	O
cells	I-cell_line	O
(	O	O
DC	O	O
)	O	O
or	O	O
tissue	O	O
DC	O	O
via	O	O
the	O	O
p55	O	O
TNF-alpha	B-protein	O
receptor	I-protein	O
.	O	O

Tissue	O	O
DC	O	O
became	O	O
more	O	O
dendritiform	O	O
in	O	O
shape	O	O
,	O	O
and	O	O
migrated	O	O
into	O	O
culture	O	O
supernatant	O	O
.	O	O

S-antigen	O	O
also	O	O
stimulated	O	O
accumulation	O	O
of	O	O
cell	B-protein	O
surface	I-protein	O
MHC	I-protein	O
class	I-protein	O
II	I-protein	O
antigen	O	O
with	O	O
a	O	O
corresponding	O	O
loss	O	O
of	O	O
acidic	B-protein	O
intracellular	I-protein	O
vesicles	I-protein	O
,	O	O
and	O	O
induced	O	O
IL-1beta	O	O
and	O	O
IL-12	B-protein	O
mRNA	I-RNA	O
expression	O	O
in	O	O
cultured	O	O
bone	O	O
marrow-derived	O	O
DC	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
cultured	O	O
splenic	O	O
DC	O	O
primed	O	O
immune	O	O
responses	O	O
to	O	O
S-antigen	O	O
in	O	O
vivo	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
other	O	O
,	O	O
exogenous	O	O
cytokine	O	O
sources	O	O
.	O	O

DC	O	O
pulsed	O	O
with	O	O
either	O	O
retinal	O	O
S-antigen	O	O
or	O	O
another	O	O
retinal	O	O
autoantigen	O	O
,	O	O
interphotoreceptor	O	O
retinoid	O	O
binding	O	O
protein	O	O
(	O	O
IRBP	O	O
)	O	O
,	O	O
were	O	O
able	O	O
to	O	O
stimulate	O	O
naive	O	O
T	O	O
cell	O	O
proliferation	O	O
in	O	O
vitro	O	O
,	O	O
but	O	O
only	O	O
S-antigen	O	O
-pulsed	O	O
DC	O	O
were	O	O
able	O	O
to	O	O
induce	O	O
an	O	O
immune	O	O
response	O	O
in	O	O
vivo	O	O
and	O	O
initiate	O	O
antibody	O	O
class	O	O
switching	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
IRBP	O	O
-pulsed	O	O
DC	O	O
had	O	O
no	O	O
detectable	O	O
in	O	O
vivo	O	O
priming	O	O
effect	O	O
and	O	O
IgG	O	O
antibody	O	O
levels	O	O
remained	O	O
suppressed	O	O
even	O	O
after	O	O
immunization	O	O
with	O	O
IRBP	O	O
in	O	O
complete	O	O
Freund	O	O
's	O	O
adjuvant	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
DC	O	O
from	O	O
the	O	O
same	O	O
precursor	O	O
population	O	O
can	O	O
either	O	O
induce	O	O
or	O	O
suppress	O	O
a	O	O
B	O	O
cell-specific	O	O
response	O	O
to	O	O
self	O	O
antigen	O	O
in	O	O
vivo	O	O
,	O	O
the	O	O
outcome	O	O
being	O	O
dependent	O	O
upon	O	O
DC	O	O
activation	O	O
at	O	O
the	O	O
time	O	O
of	O	O
antigen	O	O
uptake	O	O

